65,437 trials
Atopic Dermatitis
Primary: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade…
Cervical Cancer · Human Papillomavirus Infection
Primary: Primary Screening Participation — 144; 340; 381 Participants
Peripheral Arterial Disease · Peripheral Artery Disease · Peripheral Vascular Diseases
Primary: Specialty Consultation — 66 days
Obesity, Infant · Language Development · Parent-Child Relations
Primary: Relative Reinforcing Value of Food (RRV) Task — 0.48; 0.35; 0.5; 0.4 units on a scale
May-Thurner Syndrome
Primary: Left Common Iliac Vein Diameter — 7.5; 7.7 Millimeters (mm)
Tachycardia · Ventricular Arrythmia
Primary: Safety Outcome - Freedom From Major Complications Related to the EV ICD System and/or Procedure at 2 Weeks Post-implant — 13 Participants
SARS-CoV-2
Primary: Number of Serious Adverse Events — 0; 0; 0; 0 serious adverse events
Diabetic Macular Edema
Primary: Frequency and Severity of Ocular and Systemic Treatment Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest — 0; 2; 1; 2 Participants
Malaria
Primary: Number of Participants With Solicited Local Reactions — 0; 1; 1; 0 Participants
Inflammation · Cataract
Primary: Anterior Chamber Cell Clearing Rate — 119; 95 Participants
Von Willebrand Disease (VWD)
Primary: Spontaneous Annualized Bleeding Rate (sABR) — 1.430; 1.040; 0.000; 3.022 spontaneous bleeds per year
Inflammatory Bowel Disease · Behavioral Symptoms
Primary: IBD Symptom Severity — 75.9; 79.9; 63.5; 65.0 Score on a scale — p=0.53
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
Mild Cognitive Impairment · Mild Neurocognitive Disorder · Cognitive Decline
Primary: Total Number of Words Correctly Recalled, List Learning, California Verbal Learning Test-II, Assessed 1 Week After Intervention and Adjusted for Baseline Performance…
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Primary: Number of Participants With Adverse Events (AEs). — 16; 16; 13 Participants